Eton Pharmaceuticals (ETON) 10-K 14 Mar 24 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2023	Mar. 05, 2024	Jun. 30, 2023
Document Information [Line Items]
Entity Central Index Key	0001710340
Entity Registrant Name	Eton Pharmaceuticals, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Transition Report	false
Entity File Number	001-38738
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	37-1858472
Entity Address, Address Line One	21925 W. Field Parkway, Suite 235
Entity Address, City or Town	Deer Park
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60010-7278
City Area Code	847
Local Phone Number	787-7361
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	ETON
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 84,700,000
Entity Common Stock, Shares Outstanding		25,688,062
Auditor Firm ID	170
Auditor Name	KMJ Corbin & Company LLP
Auditor Location	Irvine, California

Balance Sheets

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Current assets:
Cash and cash equivalents	$ 21,388	$ 16,305
Accounts receivable, net	3,411	1,852
Inventories	911	557
Prepaid expenses and other current assets	1,129	1,290
Total current assets	26,839	20,004
Property and equipment, net	58	72
Intangible assets, net	4,739	4,754
Operating lease right-of-use assets, net	92	188
Other long-term assets, net	12	12
Total assets	31,740	25,030
Current liabilities:
Accounts payable	1,848	1,766
Current portion of long-term debt, net of discount	5,380	1,033
Accrued liabilities	9,013	3,662
Total current liabilities	16,241	6,461
Long-term debt, net of discount and including accrued fees	0	5,384
Operating lease liabilities, net of current portion	22	107
Total liabilities	16,263	11,952
Commitments and contingencies (Note 14)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 25,688,062 and 25,353,119 shares issued and outstanding at December 31, 2023 and 2022, respectively	26	25
Additional paid-in capital	119,521	116,187
Accumulated deficit	(104,070)	(103,134)
Total stockholders’ equity	15,477	13,078
Total liabilities and stockholders’ equity	$ 31,740	$ 25,030

Balance Sheets (Parentheticals)

Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2023	Dec. 31, 2022
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	25,688,062	25,353,119
Common stock, outstanding (in shares)	25,688,062	25,353,119

Statements of Operations

Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total net revenues	$ 31,642	$ 21,251	$ 21,832
Cost of Sales:
Total cost of sales	10,581	6,933	2,827
Gross profit	21,061	14,318	19,005
Operating expenses:
Research and development	3,322	3,996	6,235
General and administrative	18,931	18,582	14,265
Total operating expenses	22,253	22,578	20,500
Loss from operations	(1,192)	(8,260)	(1,495)
Other income (expense):
Interest and other income (expense), net	503	(761)	(1,006)
Gain on PPP loan forgiveness	0	0	365
Gain on equipment sale	0	0	181
Loss before income tax expense	(689)	(9,021)	(1,955)
Income tax expense	247	0	0
Net loss	$ (936)	$ (9,021)	$ (1,955)
Net loss per share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.36)	$ (0.08)
Weighted average number of common shares outstanding, basic and diluted (in shares)	25,645,366	25,145,657	25,207,299
License [Member]
Revenues:
Total net revenues	$ 5,500	$ 10,000	$ 19,000
Cost of Sales:
Total cost of sales	1,000	1,640	1,500
Product Sales and Royalties [Member]
Revenues:
Total net revenues	26,142	11,251	2,832
Cost of Sales:
Total cost of sales	$ 9,581	$ 5,293	$ 1,327

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balances, shares (in shares) at Dec. 31, 2020	24,312,808
Balances at Dec. 31, 2020	$ 24	$ 107,797	$ (92,158)	$ 15,663
Stock-based compensation, shares (in shares)	0
Stock-based compensation	$ 0	3,381	0	3,381
Stock option exercises, shares (in shares)	144,233
Stock option exercises	$ 1	338	0	339
Employee stock purchase plan, shares (in shares)	49,155
Employee stock purchase plan	$ 0	202	0	202
Common stock issued related to restricted stock units, shares (in shares)	25,000
Common stock issued related to restricted stock units	$ 0	0	0	0
Stock warrant exercises, shares (in shares)	94,808
Stock warrant exercises	$ 0	0	0	0
Net income (loss)	$ 0	0	(1,955)	(1,955)
Balances, shares (in shares) at Dec. 31, 2021	24,626,004
Balances at Dec. 31, 2021	$ 25	111,718	(94,113)	17,630
Stock-based compensation, shares (in shares)	0
Stock-based compensation	$ 0	4,218	0	4,218
Stock option exercises, shares (in shares)	25,000
Stock option exercises	$ 0	35	0	$ 35
Employee stock purchase plan, shares (in shares)	69,884			69,884
Employee stock purchase plan	$ 0	171	0	$ 171
Stock warrant exercises, shares (in shares)	632,231
Stock warrant exercises	$ 0	45	0	45
Net income (loss)	$ 0	0	(9,021)	(9,021)
Balances, shares (in shares) at Dec. 31, 2022	25,353,119
Balances at Dec. 31, 2022	$ 25	116,187	(103,134)	13,078
Stock-based compensation	$ 0	3,137	0	$ 3,137
Stock option exercises, shares (in shares)				407,808
Employee stock purchase plan, shares (in shares)	86,782			86,782
Employee stock purchase plan	$ 0	229	0	$ 229
Net income (loss)	$ 0	0	(936)	(936)
Stock option exercises and vesting of restricted stock units (in shares)	299,028
Stock option exercises and vesting of restricted stock units	$ 1	148	0	$ 149
Shares withheld related to net share settlement of stock option exercises (in shares)	(50,867)			(50,867)
Shares withheld related to net share settlement of stock option exercises	$ 0	(180)	0	$ (180)
Balances, shares (in shares) at Dec. 31, 2023	25,688,062
Balances at Dec. 31, 2023	$ 26	$ 119,521	$ (104,070)	$ 15,477

Statements of Cash Flows

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net income (loss)	$ (936)	$ (9,021)	$ (1,955)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation	3,137	4,218	3,381
Depreciation and amortization	901	1,774	462
Debt discount amortization	117	127	148
Gain on forgiveness of PPP loan	0	0	(365)
Gain on sale of equipment	0	0	(181)
Changes in operating assets and liabilities:
Accounts receivable	(1,559)	3,619	(5,423)
Inventories	(354)	(7)	692
Prepaid expenses and other assets	161	1,902	(1,026)
Accounts payable	53	(8)	(570)
Accrued liabilities	5,295	2,217	116
Net cash provided by (used in) operating activities	6,815	4,821	(4,721)
Cash used in investing activities
Proceeds from sale of equipment	0	0	700
Purchases of property and equipment	0	(38)	(9)
Purchase of product licensing rights	(775)	(2,750)	(3,250)
Net cash used in investing activities	(775)	(2,788)	(2,559)
Cash flows from financing activities
Debt paydown	(1,155)	(385)	(150)
Net proceeds from employee stock purchase plan and stock option and stock warrant exercises	198	251	541
Net cash (used in) provided by financing activities	(957)	(134)	391
Change in cash and cash equivalents	5,083	1,899	(6,889)
Cash and cash equivalents at beginning of year	16,305	14,406	21,295
Cash and cash equivalents at end of year	21,388	16,305	14,406
Supplemental disclosures of cash flow information
Cash paid for interest	842	730	815
Cash paid for income taxes	247	0	0
Supplemental disclosures of non-cash investing and financing activities:
Adjustment of operating lease right-of-use assets and liabilities due to tenant allowance	29	0	0
Right-of-use assets obtained in exchange for lease liabilities	$ 0	$ 188	$ 0

Note 1 - Company Overview

Note 1 - Company Overview	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1 Company Overview Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has four 1 1 three 400, 600,

Note 2 - Liquidity Consideratio

Note 2 - Liquidity Considerations	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Liquidation Basis of Accounting [Text Block]	Note 2 Liquidity Considerations As of December 31, 2023 December 31, 2023 To date, the Company has generated revenues from multiple products and expects further growth in 2024 December 31, 2023 twelve no may may

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying financial statements in accordance with GAAP. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not Segment Information The Company operates the business on the basis of a single reportable segment, which is the business of developing and commercializing prescription drug products. The Company’s chief operating decision-maker is the CEO, who evaluates the Company as a single operating segment. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The Company considers historical collection rates and the current financial status of its customers, as well as macroeconomic and industry-specific factors when evaluating potential credit losses. Historically, the Company's accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of specialty pharmacies and large wholesale pharmaceutical distributors. Given the size and creditworthiness of these customers, we have not not December 31, 2023 2022 Inventories The Company values its inventories at the lower of cost or net realizable value using the first first December 31, 2023 2022 December 31, 2023 2022, December 31, 2023 2022 Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives. Computer hardware and software is depreciated over three five not Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized. Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 November 2021, ten 2019 five 14 June 2022 six December 31, 2022. Q1 2022 five three June 30, 2022. September 2022, five October 2023, five December 31, 2023 December 31, 2023, 2022 2021 five 2024 2028 Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739 Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023, 2022 2021 Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method. Leases The Company accounts for leases in accordance with ASC Topic 842 not The Company measures right-of-use assets based on the corresponding lease liabilities adjusted for (i) any prepayments made to the lessor at or before the commencement date, (ii) initial direct costs it incurs, and (iii) any incentives under the lease. In addition, the Company evaluates the recoverability of its right-of-use assets for possible impairment in accordance with its long-lived assets policy. Operating leases are reflected on the balance sheets as operating lease right-of-use assets, current accrued liabilities and long-term operating lease liabilities. The Company does not December 31, 2023 2022 The Company commences recognizing operating lease expense when the lessor makes the underlying asset available for use by the Company and the operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are expensed as incurred. The Company does not twelve Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses. Concentrations of Credit Risk, Sources of Supply and Significant Customers The Company is subject to credit risk for its cash and cash equivalents which are invested in money market funds and U.S. treasury bills from time to time. The Company maintains its cash and cash equivalent balances with one The Company is dependent on third The Company is also subject to credit risk from its accounts receivable related to product sales as it extends credit based on an evaluation of the customer’s financial condition, and collateral is not no December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 2023 December 31, 2023 2022 December 31, 2022 Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 606 606, 606, five At contract inception, once the contract is determined to be within the scope of ASC 606, The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve not twelve Milestone Payments not not not Royalties Significant Financing Component one The Company sells its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nisitinone products to pharmacy distributor customers which provide order fulfilment and inventory storage/distribution services. The Company may third “3PL” 3PL 3PL no For its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are estimated and recorded as a reduction of net revenues at the date of sale/shipment. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell products at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. Because of the shelf life of the product and the Company’s lengthy return period, there may The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks and the impact of other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no The Company stores its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone inventory at its pharmacy distributor customer locations, and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. The Company may not Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment. Cost of Product Sales Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third 3PL 3PL Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as Series A Preferred, unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. No 2023 2022 2021 December 31, 2023, 2022 2021 9 Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 718 The Company estimates the fair value of stock-based option awards using the BSM. The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero zero Income Taxes As part of the process of preparing the Company’s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not December 31, 2023 2022 The Company accounts for income taxes under the provisions of ASC 740 December 31, 2023 2022 no December 31, 2023 2022 not December 31, 2023, 2022 2021 December 31, 2023 2017 2023 Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2023 2022 Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and long-term debt obligation. The carrying amounts of these financial instruments, except for the long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the long-term debt obligation approximate its fair value. Impact of Recent Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, No. 2021 01, Reference Rate Reform (Topic 848 2021 01" No. 2020 04 No. 2021 01 No. 2020 04 No. 2021 01 December 31, 2022. December 2022, No. 2022 06, Reference Rate Reform (Topic 848 Topic 848 848 December 31, 2024. August 22, 2023. no In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 316 may No. 2016 13, No. 2018 19, Codification Improvements to Topic 326, not No. 2016 13, No. 2019 04 not No. 2016 13 not January 1, 2023 not no

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4 Property and Equipment Property and equipment consist of the following: December 31, December 31, 2023 2022 Computer hardware and software $ 187 $ 177 Furniture and fixtures 111 112 Equipment 52 52 Leasehold improvements 103 71 Construction in progress — 12 453 424 Less: accumulated depreciation and amortization (395 ) (352 ) Property and equipment, net $ 58 $ 72 Depreciation expense for the years ended December 31, 2023, 2022 2021

Note 5 - Debt

Note 5 - Debt	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Long-Term Debt [Text Block]	Note 5 Debt SWK Loan In November 2019, second 100. March 2020, 14 March 2020 6 100 September 2020. August 2020. February 2022 three November 2024 February 2021, not In connection with the initial $5,000 borrowed in November 2019, seven In connection with the additional $2,000 borrowed in August 2020, seven These warrants (the “SWK Warrants”) are exercisable immediately and have a term of seven In April 2022, May 2023 3 12 December 31, 2022. June 2023, August 2023 The Company recorded interest expense of $1,060, $955 and $1,042 in 2023, 2022 2021 December 31, 2023 2022 Note 5 Debt (continued) The table below reflects the future annual payments for the SWK loan principal and interest as of December 31, 2023 Amount 2024 6,483 Total payments 6,483 Less: amount representing interest (1,023 ) Loan payable, gross 5,460 Less: unamortized discount (80 ) Debt, net of unamortized discount $ 5,380 PPP loan On May 4, 2020, May 20, 2021, December 31, 2021 EIDL loan On July 21, 2020, July 2021.

Note 6 - Common Stock

Note 6 - Common Stock	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Equity [Text Block]	Note 6 Common Stock The Company has 50,000,000 authorized shares of $0.001 par value common stock under its Amended and Restated Certificate of Incorporation. Note 6 Common Stock (continued) For the years ended December 31, 2023 2022 2018 8 December 31, 2023. December 31, 2023 2022 December 31, 2023 April 2021, 2022,

Note 7 - Common Stock Warrants

Note 7 - Common Stock Warrants	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Stockholders' Equity Note, Warrants or Rights Warrants Disclosure [TextBlock]	Note 7 Common Stock Warrants Listed below is a summary of warrants outstanding as of December 31, 2023 Description of Warrants No. of Shares Exercise Price SWK Warrants – Debt (Tranche #1) 51,239 $ 5.86 SWK Warrants – Debt (Tranche #2) 18,141 $ 6.62 Total 69,380 6.05 (Avg) The holders of these warrants or their permitted transferees, are entitled to rights with respect to the registration under the Securities Act of their shares that are converted to common stock, including demand registration rights and piggyback registration rights. These rights are provided under the terms of a registration rights agreement between the Company and the investors. On June 26, 2022, 2017 December 26, 2022 No December 31, 2022. A rollforward of the warrants outstanding is listed in the table below: No. of Shares Balance as of the beginning of the year 483,380 Expiration of National Securities Corp – November 2018 issuance (414,000 ) Balance as of the end of the year 69,380 There were 1,067,242 warrants exercised on a cashless basis in 2022 2021 2022 2021. 2023.

Note 8 - Share-based Payment Aw

Note 8 - Share-based Payment Awards	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	Note 8 Share-Based Payment Awards The Company’s board of directors and stockholders approved the Eton Pharmaceuticals, Inc. 2017 May 2017 ( “2017 November 2018, 2018 “2018 2017 2017 2018 2018 December 31, 2023 Note 8 Share-Based Payment Awards (continued) Shares that are expired, terminated, surrendered or canceled without having been fully exercised will be available for future awards under the 2018 2018 January 1, 2019 January 1, 2028, December 31, January 1, 2021, December 31, 2020. January 1, 2022, December 31, 2021. January 1, 2023, December 31, 2022. not To date, all stock options issued have been non-qualified stock options, and the exercise prices were set at the fair value for the shares at the dates of grant. Options typically have a ten July 2017 July 2022 not five not not In July 2022 September 2022, two one May 2022 July 2022. 90 may April 2023. No December 31, 2022. For the years ended December 31, 2023, 2022 2021 Stock Options The following table summarizes stock option activity during the year ended December 31, 2023 Weighted Average Weighted Average Remaining Exercise Contractual Aggregate Intrinsic Shares Price Term Value Options outstanding as of January 1, 2023 4,402,292 $ 4.71 Issued 1,108,291 3.51 Exercised (407,808 ) 2.23 Forfeited/Cancelled (263,549 ) 5.94 Options outstanding as of December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 Options exercisable at December 31, 2023 3,399,896 $ 4.78 6.7 $ 2,432 Options vested and expected to vest at December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had strike prices lower than the fair value of the Company’s common stock at December 31. 2023 Note 8 Share-Based Payment Awards (continued) There were 207,626 and 25,000 shares issued for exercise of stock options during the years ended December 31, 2023 2022 The assumptions used to calculate the estimated fair value of options granted during the years ended December 31, 2023, 2022 2021 December 31, 2023 December 31, 2022 December 31, 2021 Expected dividends — % — % — % Expected volatility 70 % 70 % 70 - 80 % Risk-free interest rate 3.5 - 4.7 % 1.5 - 3.9 % 0.9 - 1.4 % Expected term (in years) 6.3 5.9 6.0 Weighted average grant date fair value $ 2.32 $ 2.32 $ 5.64 Expected Term — The Company has opted to use the “simplified method” for estimating the expected term of options granted to employees and directors, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option (generally 10 years). The expected term of options granted to non-employees equals the contractual life of the options. Expected Volatility — Expected volatilities are based on the Company's historical volatility subsequent to our IPO, which we believe represents the most accurate basis for estimating expected future volatility under the current conditions. Risk-Free Interest Rate — The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company’s stock options. Expected Dividend — The Company has not not Fair value of Common Stock —The Company uses the closing stock price on the date of grant for the fair value of the common stock. As of December 31, 2023 Restricted Stock Units (RSUs) The following table summarizes restricted stock unit activity during the year ended December 31, 2023 Weighted Average Grant-Date Number of Units Fair Value Per Unit Outstanding and unvested as of January 1, 2023 369,606 $ 2.63 Granted — — Vested (91,402 ) $ 2.63 Forfeited (4,000 ) $ 2.63 Outstanding and unvested as of December 31, 2023 274,204 $ 2.63 Stock-based compensation related to RSUs was $239 and $114 for the years ended December 31, 2023 2022 December 31, 2023 Note 8 Share-Based Payment Awards (continued) Employee Stock Purchase Plan In December 2018, January 1 December 31 The terms of the ESPP permit employees of the Company to use payroll deductions to purchase stock at a price per share that is at least the lesser of ( 1 first 2 twelve two six June 10 December 10 six twelve The Company recorded an expense of $135, $128, and $73 in 2023, 2022 2021 December 31, 2023 2022 2023, 2022 2021 2023 2022 December 31, 2023 2022 December 31, 2023

Note 9 - Basic and Diluted Net

Note 9 - Basic and Diluted Net Loss per Common Share	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	Note 9 Basic and Diluted Net Loss per Common Share Basic and diluted net loss per share is computed using the weighted average number of shares of common stock outstanding during the period. Common stock equivalents (using the treasury stock and “if converted” method) from stock options, unvested RSAs and RSUs, and warrants at December 31, 2023, 2022 2021 The following table shows the computation of basic and diluted net loss per common share: Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Net loss $ (936 ) $ (9,021 ) $ (1,955 ) Weighted average common shares outstanding (basic and diluted) 25,645,366 25,145,657 25,207,299 Net loss per common share (basic and diluted) $ (0.04 ) $ (0.36 ) $ (0.08 )

Note 10 - Related-party Transac

Note 10 - Related-party Transactions	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 10 Related-Party Transactions Harrow The Chief Executive Officer of Harrow Health, Inc. (“Harrow”) was a member of the Company’s board of directors until March 17, 2021 April 2021 December 31, 2023 In March 2021, May 2021 Chief Executive Officer The CEO has a partial interest in a company that the Company has partnered with for its EM- 100/Alaway The Company acquired the exclusive rights to sell the EM- 100 August 11, 2017 first two On February 18, 2019, 100, two one first one first first December 31, 2023 100 February 18, 2019 twelve September 2020, December 31, 2023 December 31, 2022 March 24, 2023.

Note 11 - Leases

Note 11 - Leases	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 11 Leases The Company recognizes a right-of-use (“ROU”) asset and a lease liability on the balance sheet for substantially all leases, including operating leases, and separates lease components from non-lease components related to its office space lease. In January 2018, October 2020, two March 2023 November 2022, two March 2025 In March 2018, March 2018. November 2020, June 2021 not The Company does not 1 2 3 not not The Company’s leases do not October 2020, November 2022, Note 11 Leases (continued) The Company’s operating lease cost as presented in the “Research and Development” and “General and Administrative” captions in the statements of operations was $0, $0, and $9 and $67, $82, and $86 for the years ended December 31, 2023, 2022 2021 December 31, 2023, 2022 2021 December 31, 2023, 2022, 2021, December 31, 2023, 2022 2021 December 31, 2023 The table below presents the lease-related assets and liabilities recorded on the balance sheet as of December 31, 2023 Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 92 Total leased assets $ 92 Liabilities Operating lease liabilities, current Accrued liabilities $ 53 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 22 Total operating lease liabilities $ 75 The Company’s future annual lease commitments as of December 31, 2023 Total 2024 2025 2026 Undiscounted lease payments $ 81 $ 58 $ 23 $ — Less: Imputed interest (6 ) Total lease liabilities $ 75

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 12 Income Taxes The provision for income taxes for the Company consists of the following for the years ended December 31, 2023, 2022 2021 Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Current: Federal $ 61 $ — $ — State 186 — — Total current expense 247 — — Deferred: Federal (85 ) 2,272 460 State (31 ) 812 185 Change in valuation allowance 116 (3,084 ) (645 ) Total deferred expense — — — Total provision $ 247 $ — $ — Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Note 12 Income Taxes (continued) The significant components of the Company’s deferred tax assets as of December 31, 2023 2022 December 31, December 31, 2023 2022 Net operating losses $ 15,447 $ 17,183 Stock-based expenses 3,372 3,090 Accruals and other 2,697 1,359 Total deferred tax assets 21,516 21,632 Valuation allowance (21,516 ) (21,632 ) Net deferred tax assets $ — $ — Based on the uncertainty of future taxable income at this time management believes a 100% valuation reserve for the $21,516 and $21,632 deferred tax assets at December 31, 2023 2022 A reconciliation of the statutory federal tax rate to effective tax rate is shown below: Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Provision (benefit) at statutory rate 21.0 % (21.0 )% (21.0 )% Permanent items (primarily warrants and stock compensation) 39.1 (3.3 ) (2.5 ) State tax benefit 6.5 (8.7 ) (9.5 ) Federal rate change — — — Other items — — — Increase (decrease) in valuation allowance (30.7 ) 33.0 33.0 Income tax expense 35.9 % — % — % The Company has a federal and state NOL carryforward of $54,190 as of December 31, 2023 December 31, 2017 may 80% 2029. In addition, under Sections 382 383 1986, 50% three may

Note 13 - Employee Savings Plan

Note 13 - Employee Savings Plan	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 13 Employee Savings Plan The Company established an employee savings plan pursuant to Section 401 January 1, 2018. December 31, 2023, 2022 2021

Note 14 - Commitments and Conti

Note 14 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 14 Commitments and Contingencies Legal The Company is subject to legal proceedings and claims that may not may License and Product Development Agreements The Company has entered into various agreements in addition to those discussed above which are described below. The three three 2021, three June 2023 Prior to January 1, 2022, third 101 November 2021, December 2021. December 31, 2021 January 2022. On January 23, 2019, 104” 104. 104 November 2022. Note 14 Commitments and Contingencies (continued) In March 2020, September 2020, For the initial licensing milestone fee, the Company paid Diurnal $3,500 in cash and issued 379,474 shares of its common stock to Diurnal which were valued at $1,264 based on the Company’s closing stock price of $3.33 on March 26, 2020. 2023 January 2024 December 2023, In June 2021, March 2022 In October 2021, October 2021. December 2021. In June 2022, twelve December 31, 2022. twelve December 31, 2022. In September 2022, January 2022. November 2023, In March 2023, 600 July 2023 first In October 2023, May 2023. Indemnification As permitted under Delaware law and in accordance with the Company’s Amended and Restated Bylaws, the Company is required to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors and officers. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not December 31, 2023 2022

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Dec. 31, 2023
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	9B. Insider Trading Arrangements and Related Disclosure During the three December 31, 2023, none 10b5 1 10b5 1 408 We are committed to promoting high standards of ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, we have adopted our Insider Trading Policy governing the purchase, sale, and/or other dispositions of our securities by our directors, officers, employees and designated contractors. We believe our Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. A copy of our Insider Trading Policy, including any amendments thereto, is filed as Exhibit 19.1 10 9C. Not
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The Company has prepared the accompanying financial statements in accordance with GAAP.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Significant estimates and assumptions reflected in these financial statements include, but are not
Segment Reporting, Policy [Policy Text Block]	Segment Information The Company operates the business on the basis of a single reportable segment, which is the business of developing and commercializing prescription drug products. The Company’s chief operating decision-maker is the CEO, who evaluates the Company as a single operating segment.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three
Accounts Receivable [Policy Text Block]	Accounts Receivable Accounts receivable are recorded at the invoiced amount and are non-interest bearing. Accounts receivable are recorded net of allowances for doubtful accounts, cash discounts for prompt payment, distribution fees, chargebacks and returns and allowances. The Company considers historical collection rates and the current financial status of its customers, as well as macroeconomic and industry-specific factors when evaluating potential credit losses. Historically, the Company's accounts receivable balances have been highly concentrated with a select number of customers, consisting primarily of specialty pharmacies and large wholesale pharmaceutical distributors. Given the size and creditworthiness of these customers, we have not not December 31, 2023 2022
Inventory, Policy [Policy Text Block]	Inventories The Company values its inventories at the lower of cost or net realizable value using the first first December 31, 2023 2022 December 31, 2023 2022, December 31, 2023 2022
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost. Depreciation of property and equipment is computed utilizing the straight-line method based on the following estimated useful lives. Computer hardware and software is depreciated over three five not Maintenance and repairs are charged to expense as incurred, while renewals and improvements are capitalized.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets The Company capitalizes payments it makes for licensed products when the payment is based on FDA approval for the product and the cost is recoverable based on expected future cash flows from the product. The cost is amortized on a straight-line basis over the estimated useful life of the product commencing on the approval date in accordance with Accounting Standards Codification (“ASC”) 350 November 2021, ten 2019 five 14 June 2022 six December 31, 2022. Q1 2022 five three June 30, 2022. September 2022, five October 2023, five December 31, 2023 December 31, 2023, 2022 2021 five 2024 2028 Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not December 31, 2023, 2022 2021
Debt, Policy [Policy Text Block]	Debt Issuance Costs and Debt Discount and Detachable Debt-Related Warrants Costs incurred to issue debt are deferred and recorded as a reduction to the debt balance in the accompanying balance sheets. The Company amortizes debt issuance costs over the expected term of the related debt using the effective interest method. Debt discounts relate to the relative fair value of warrants issued in conjunction with the debt and are also recorded as a reduction to the debt balance and accreted over the expected term of the debt to interest expense using the effective interest method.
Lessee, Leases [Policy Text Block]	Leases The Company accounts for leases in accordance with ASC Topic 842 not The Company measures right-of-use assets based on the corresponding lease liabilities adjusted for (i) any prepayments made to the lessor at or before the commencement date, (ii) initial direct costs it incurs, and (iii) any incentives under the lease. In addition, the Company evaluates the recoverability of its right-of-use assets for possible impairment in accordance with its long-lived assets policy. Operating leases are reflected on the balance sheets as operating lease right-of-use assets, current accrued liabilities and long-term operating lease liabilities. The Company does not December 31, 2023 2022 The Company commences recognizing operating lease expense when the lessor makes the underlying asset available for use by the Company and the operating lease expense is recognized on a straight-line basis over the term of the lease. Variable lease payments are expensed as incurred. The Company does not twelve
Patent Costs [Policy Text Block]	Patent Costs All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the successful award of a patent and the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk, Sources of Supply and Significant Customers The Company is subject to credit risk for its cash and cash equivalents which are invested in money market funds and U.S. treasury bills from time to time. The Company maintains its cash and cash equivalent balances with one The Company is dependent on third The Company is also subject to credit risk from its accounts receivable related to product sales as it extends credit based on an evaluation of the customer’s financial condition, and collateral is not no December 31, 2023 2022 December 31, 2023 2022 December 31, 2023 2022 2023 December 31, 2023 2022 December 31, 2022
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition for Contracts with Customers The Company accounts for contracts with its customers in accordance with ASC 606 606 606, 606, five At contract inception, once the contract is determined to be within the scope of ASC 606, The Company recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) each performance obligation is satisfied at a point in time or over time, and if over time this is based on the use of an output or input method. Any amounts received prior to revenue recognition will be recorded as deferred revenue. Amounts expected to be recognized as revenue within the twelve not twelve Milestone Payments not not not Royalties Significant Financing Component one The Company sells its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nisitinone products to pharmacy distributor customers which provide order fulfilment and inventory storage/distribution services. The Company may third “3PL” 3PL 3PL no For its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone products, the Company bills at the initial product list price which are subject to offsets for patient co-pay assistance and potential state Medicaid reimbursements which are estimated and recorded as a reduction of net revenues at the date of sale/shipment. Selling prices initially billed to wholesalers are subject to discounts for prompt payment and subsequent chargebacks when the wholesalers sell products at negotiated discounted prices to members of certain group purchasing organizations (“GPOs”) and government programs. Because of the shelf life of the product and the Company’s lengthy return period, there may The Company estimates the transaction price when it receives each purchase order taking into account the expected reductions of the selling price initially billed to the wholesaler/distributor arising from all of the above factors. The Company has developed estimates for future returns and chargebacks and the impact of other discounts and fees it pays. When estimating these adjustments to the transaction price, the Company reduces it sufficiently to be able to assert that it is probable that there will be no The Company stores its ALKINDI SPRINKLE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone inventory at its pharmacy distributor customer locations, and sales are recorded when stock is pulled and shipped to fulfill specific patient orders. The Company may not Upon recognition of revenue from product sales, the estimated amounts of credit for product returns, chargebacks, distribution fees, prompt payment discounts, state Medicaid and GPO fees are included in sales reserves, accrued liabilities and net accounts receivable. The Company monitors actual product returns, chargebacks, discounts and fees subsequent to the sale. If these amounts end up differing from its estimates, it will make adjustments to these allowances, which are applied to increase or reduce product sales revenue and earnings in the period of adjustment.
Cost of Goods and Service [Policy Text Block]	Cost of Product Sales Cost of product sales consists of the profit-sharing and royalty fees with the Company’s product licensing and development partners, the purchase costs for finished products from third 3PL 3PL
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Research and development (“R&D”) expenses include both internal R&D activities and external contracted services. Internal R&D activity expenses include salaries, benefits and stock-based compensation and other costs to support the Company’s R&D operations. External contracted services include product development efforts such as certain product licensor milestone payments, clinical trial activities, manufacturing and control-related activities and regulatory costs. R&D expenses are charged to operations as incurred. The Company reviews and accrues R&D expenses based on services performed and relies upon estimates of those costs applicable to the stage of completion of each project. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. Upfront payments and milestone payments made for the licensing of technology for products that are not
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Share Basic net income (loss) per common share is computed by dividing net income (loss) attributable to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) attributable to common stockholders for the period by the weighted average number of common and common equivalent shares, such as Series A Preferred, unvested restricted stock, stock options and warrants that are outstanding during the period. Common stock equivalents are excluded from the computation when their inclusion would be anti-dilutive. No 2023 2022 2021 December 31, 2023, 2022 2021 9
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of ASC 718 718 The Company estimates the fair value of stock-based option awards using the BSM. The BSM requires the input of subjective assumptions, including the expected stock price volatility, the calculation of expected term, forfeitures and the fair value of the underlying common stock on the date of grant, among other inputs. The risk-free interest rate was determined from the implied yields for zero zero
Income Tax, Policy [Policy Text Block]	Income Taxes As part of the process of preparing the Company’s financial statements, the Company must estimate the actual current tax liabilities and assess temporary differences resulting from differing treatment of items for tax and accounting purposes. These differences result in deferred tax assets and liabilities, which are included within the balance sheets. The Company must assess the likelihood that the deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not December 31, 2023 2022 The Company accounts for income taxes under the provisions of ASC 740 December 31, 2023 2022 no December 31, 2023 2022 not December 31, 2023, 2022 2021 December 31, 2023 2017 2023 Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no December 31, 2023 2022
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements We measure certain of our assets and liabilities at fair value. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value accounting requires characterization of the inputs used to measure fair value into a three Level 1 Level 2 Level 3 Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may The Company’s financial instruments included cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities and long-term debt obligation. The carrying amounts of these financial instruments, except for the long-term debt obligation, approximate their fair values due to the short-term maturities of these instruments. Based on borrowing rates currently available to the Company, the carrying value of the long-term debt obligation approximate its fair value.
New Accounting Pronouncements, Policy [Policy Text Block]	Impact of Recent Accounting Pronouncements In March 2020, No. 2020 04, Reference Rate Reform (Topic 848 January 2021, No. 2021 01, Reference Rate Reform (Topic 848 2021 01" No. 2020 04 No. 2021 01 No. 2020 04 No. 2021 01 December 31, 2022. December 2022, No. 2022 06, Reference Rate Reform (Topic 848 Topic 848 848 December 31, 2024. August 22, 2023. no In June 2016, 2016 13, Financial Instruments-Credit Losses (Topic 316 may No. 2016 13, No. 2018 19, Codification Improvements to Topic 326, not No. 2016 13, No. 2019 04 not No. 2016 13 not January 1, 2023 not no

Note 3 - Summary of Significa_2

Note 3 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Amortization Expense 2024 $ 880 2025 880 2026 880 2027 756 2028 423 Thereafter 920 Total estimated amortization expense $ 4,739

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, December 31, 2023 2022 Computer hardware and software $ 187 $ 177 Furniture and fixtures 111 112 Equipment 52 52 Leasehold improvements 103 71 Construction in progress — 12 453 424 Less: accumulated depreciation and amortization (395 ) (352 ) Property and equipment, net $ 58 $ 72

Note 5 - Debt (Tables)

Note 5 - Debt (Tables)	12 Months Ended
	Dec. 31, 2023
SWK Credit Agreement [Member]
Notes Tables
Schedule of Maturities of Long-Term Debt [Table Text Block]	Amount 2024 6,483 Total payments 6,483 Less: amount representing interest (1,023 ) Loan payable, gross 5,460 Less: unamortized discount (80 ) Debt, net of unamortized discount $ 5,380

Note 7 - Common Stock Warrants

Note 7 - Common Stock Warrants (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Description of Warrants No. of Shares Exercise Price SWK Warrants – Debt (Tranche #1) 51,239 $ 5.86 SWK Warrants – Debt (Tranche #2) 18,141 $ 6.62 Total 69,380 6.05 (Avg)
Schedule of Rollforward of Warrants Outstanding [Table Text Block]	No. of Shares Balance as of the beginning of the year 483,380 Expiration of National Securities Corp – November 2018 issuance (414,000 ) Balance as of the end of the year 69,380

Note 8 - Share-based Payment _2

Note 8 - Share-based Payment Awards (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Weighted Average Remaining Exercise Contractual Aggregate Intrinsic Shares Price Term Value Options outstanding as of January 1, 2023 4,402,292 $ 4.71 Issued 1,108,291 3.51 Exercised (407,808 ) 2.23 Forfeited/Cancelled (263,549 ) 5.94 Options outstanding as of December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467 Options exercisable at December 31, 2023 3,399,896 $ 4.78 6.7 $ 2,432 Options vested and expected to vest at December 31, 2023 4,839,226 $ 4.57 7.3 $ 3,467
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	December 31, 2023 December 31, 2022 December 31, 2021 Expected dividends — % — % — % Expected volatility 70 % 70 % 70 - 80 % Risk-free interest rate 3.5 - 4.7 % 1.5 - 3.9 % 0.9 - 1.4 % Expected term (in years) 6.3 5.9 6.0 Weighted average grant date fair value $ 2.32 $ 2.32 $ 5.64
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Weighted Average Grant-Date Number of Units Fair Value Per Unit Outstanding and unvested as of January 1, 2023 369,606 $ 2.63 Granted — — Vested (91,402 ) $ 2.63 Forfeited (4,000 ) $ 2.63 Outstanding and unvested as of December 31, 2023 274,204 $ 2.63

Note 9 - Basic and Diluted Ne_2

Note 9 - Basic and Diluted Net Loss per Common Share (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Net loss $ (936 ) $ (9,021 ) $ (1,955 ) Weighted average common shares outstanding (basic and diluted) 25,645,366 25,145,657 25,207,299 Net loss per common share (basic and diluted) $ (0.04 ) $ (0.36 ) $ (0.08 )

Note 11 - Leases (Tables)

Note 11 - Leases (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Lessee, Operating Lease, Disclosure [Table Text Block]	Assets Classification Operating lease right-of-use assets Operating lease right-of-use assets, net $ 92 Total leased assets $ 92 Liabilities Operating lease liabilities, current Accrued liabilities $ 53 Operating lease liabilities, noncurrent Operating lease liabilities, net of current portion 22 Total operating lease liabilities $ 75
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	Total 2024 2025 2026 Undiscounted lease payments $ 81 $ 58 $ 23 $ — Less: Imputed interest (6 ) Total lease liabilities $ 75

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Current: Federal $ 61 $ — $ — State 186 — — Total current expense 247 — — Deferred: Federal (85 ) 2,272 460 State (31 ) 812 185 Change in valuation allowance 116 (3,084 ) (645 ) Total deferred expense — — — Total provision $ 247 $ — $ —
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	December 31, December 31, 2023 2022 Net operating losses $ 15,447 $ 17,183 Stock-based expenses 3,372 3,090 Accruals and other 2,697 1,359 Total deferred tax assets 21,516 21,632 Valuation allowance (21,516 ) (21,632 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year ended Year ended Year ended December 31, December 31, December 31, 2023 2022 2021 Provision (benefit) at statutory rate 21.0 % (21.0 )% (21.0 )% Permanent items (primarily warrants and stock compensation) 39.1 (3.3 ) (2.5 ) State tax benefit 6.5 (8.7 ) (9.5 ) Federal rate change — — — Other items — — — Increase (decrease) in valuation allowance (30.7 ) 33.0 33.0 Income tax expense 35.9 % — % — %

Note 2 - Liquidity Considerat_2

Note 2 - Liquidity Considerations (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Retained Earnings (Accumulated Deficit)	$ (104,070)	$ (103,134)
Net Income (Loss) Attributable to Parent	(936)	(9,021)	$ (1,955)
Cash and Cash Equivalents, at Carrying Value	$ 21,388	$ 16,305

Note 3 - Summary of Significa_3

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	1 Months Ended			3 Months Ended	12 Months Ended
	Oct. 31, 2023	Sep. 30, 2022	Nov. 30, 2021	Mar. 31, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2019	Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss					$ 129	$ 262
Inventory Valuation Reserves					76	62
Payments to Acquire Intangible Assets					775	2,750	$ 3,250
Finite-Lived Intangible Assets, Accumulated Amortization					1,286
Amortization of Intangible Assets					790	1,617	204
Impairment, Long-Lived Asset, Held-for-Use					0	0	$ 0
Finance Lease, Liability					$ 0	$ 0
Percentage for Valuation Reserve Against Deferred Tax Assets					100%	100%
Unrecognized Tax Benefits					$ 0	$ 0
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | AnovoRx [Member]
Concentration Risk, Percentage					78.20%	45.50%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | AnovoRx [Member]
Concentration Risk, Percentage					97.40%	79.80%
Carglumic Acid Product Rights [Member]
Payments to Acquire Intangible Assets			$ 3,250
Finite-Lived Intangible Asset, Useful Life (Year)			10 years
Biorphen [Member]
Payments to Acquire Intangible Assets								$ 750
Finite-Lived Intangible Asset, Useful Life (Year)								5 years
Finite-Lived Intangible Assets, Accumulated Amortization									$ 275
Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year						$ 75
Rezipres Product [Member]
Payments to Acquire Intangible Assets				$ 750
Finite-Lived Intangible Asset, Useful Life (Year)				5 years
Finite-Lived Intangible Assets, Accumulated Amortization									$ 738
Betaine Anhydrous Product Rights [Member]
Payments to Acquire Intangible Assets		$ 2,125
Finite-Lived Intangible Asset, Useful Life (Year)		5 years
Nitisinone Product Rights [Member]
Payments to Acquire Intangible Assets	$ 650
Finite-Lived Intangible Asset, Useful Life (Year)	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)					5 years

Note 3 - Summary of Significa_4

Note 3 - Summary of Significant Accounting Policies - Schedule of Intangible Assets Amortization Expense (Details) $ in Thousands	Dec. 31, 2023 USD ($)
2024	$ 880
2025	880
2026	880
2027	756
2028	423
Thereafter	920
Total estimated amortization expense	$ 4,739

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Depreciation	$ 44	$ 66	$ 155

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Computer hardware and software	$ 187	$ 177
Furniture and fixtures	111	112
Equipment	52	52
Leasehold improvements	103	71
Construction in progress	0	12
Property, Plant and Equipment, Gross	453	424
Less: accumulated depreciation and amortization	(395)	(352)
Property and equipment, net	$ 58	$ 72

Note 5 - Debt (Details Textual)

Note 5 - Debt (Details Textual)								1 Months Ended		12 Months Ended			33 Months Ended
	Apr. 05, 2022 USD ($)	May 20, 2021 USD ($)	Aug. 11, 2020 USD ($)	Jul. 21, 2020 USD ($)	May 04, 2020 USD ($)	Nov. 30, 2019 USD ($) $ / shares shares	Nov. 13, 2019 USD ($)	Aug. 31, 2020 USD ($) $ / shares shares	Nov. 30, 2019 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 USD ($) $ / shares	Dec. 31, 2021 USD ($)	Nov. 13, 2024	Sep. 30, 2023 $ / shares	Jun. 26, 2022 $ / shares shares	Nov. 13, 2020 USD ($)	Mar. 31, 2020 USD ($)
Long-Term Debt, Gross										$ 5,460,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares															467,242
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares															$ 3
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares										$ 0.001	$ 0.001			$ 0.001
Long-Term Debt, Current Maturities										$ 5,380,000	$ 1,033,000
Interest Expense										1,060,000	955,000	$ 1,042,000
Amortization of Debt Discount (Premium)										117,000	127,000	148,000
Gain (Loss) on Extinguishment of Debt										0	0	365,000
SWK Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares						51,239		18,141	51,239
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares						$ 5.86		$ 6.62	$ 5.86
Warrants and Rights Outstanding						$ 51,239			$ 51,239
Fair Value Adjustment of Warrants								$ 94,000	$ 226,000
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares						$ 5.75		$ 6.85	$ 5.75
Warrants and Rights Outstanding, Term (Year)						7 years		7 years	7 years
SWK Warrants [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input						95		95	95
SWK Warrants [Member] | Measurement Input, Expected Dividend Rate [Member]
Warrants and Rights Outstanding, Measurement Input						0		0	0
SWK Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]
Warrants and Rights Outstanding, Measurement Input						1.8		0.4	1.8
SWK Credit Agreement [Member] | SWK Holdings Corporation [Member]
Debt Instrument, Face Amount							$ 10,000,000
Proceeds from Issuance of Debt						$ 5,000,000	5,000,000
Debt Instrument, Covenant Agreement, Additional Amount							$ 5,000,000
Debt Instrument, Covenant Requirements, Minimum Cash Balance																$ 3,000,000
SWK Credit Agreement [Member] | SWK Holdings Corporation [Member] | Scenario, Plan [Member]
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed													5.50%
The Amended Agreement [Member]
Debt Instrument, Increase, Accrued Interest										$ 332,000	$ 231,000
The Amended Agreement [Member] | SWK Holdings Corporation [Member]
Proceeds from Issuance of Debt			$ 2,000,000					$ 2,000,000
Debt Instrument, Covenant Agreement, Additional Amount																	$ 3,000,000
Long-Term Debt, Gross																	$ 2,000,000
Debt Instrument, Basis Spread on Variable Rate	8%
Debt Instrument, LIBOR Floor Rate	2%
Long-Term Debt, Current Maturities	$ 1,033,000
The Amended Agreement [Member] | SWK Holdings Corporation [Member] | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate										8.26%
Debt Instrument SOFR Floor Rate										5%
Paycheck Protection Program Loan [Member]
Proceeds from Issuance of Debt					$ 361,000
Interest Expense		$ 4,000
Gain (Loss) on Extinguishment of Debt												$ 365,000
Economic Injury Disaster Loan Program [Member]
Proceeds from Issuance of Debt				$ 150,000
Interest Expense				$ 6,000

Note 5 - Debt - Schedule of Fut

Note 5 - Debt - Schedule of Future Payments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
2024	$ 6,483
Total payments	6,483
Less: amount representing interest	(1,023)
Long-Term Debt, Gross	5,460
Less: unamortized discount	(80)
Current portion of long-term debt, net of discount	$ 5,380	$ 1,033

Note 6 - Common Stock (Details

Note 6 - Common Stock (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	12 Months Ended
	Apr. 30, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Jun. 26, 2022
Common Stock, Shares Authorized (in shares)		50,000,000	50,000,000		50,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001	$ 0.001		$ 0.001
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		407,808
Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)		50,867
Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation		$ 180
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)	25,000	86,782	69,884
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (in shares)		91,402
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)						467,242
Common Stock Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)		0	1,067,242	135,650
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			632,231	94,808
The Two Thousand Eighteen Equity Incentive Plan Member
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		207,626	25,000
The Two Thousand Eighteen Equity Incentive Plan Member | Cashless Stock Awards [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		407,808

Note 7 - Common Stock Warrant_2

Note 7 - Common Stock Warrants (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jun. 26, 2022
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				467,242
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3
Common Stock Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		632,231	94,808
Class of Warrant or Right, Exercised During Period (in shares)	0	1,067,242	135,650
Class of Warrant or Right, Exercised, Intrinsic Value		$ 2,367	$ 806
General and Administrative Expense [Member]
Class of Warrant or Right, Modification Expense		$ 244

Note 7 - Common Stock Warrant_3

Note 7 - Common Stock Warrants - Schedule of Warrants Outstanding (Details) - $ / shares	Dec. 31, 2023	Jun. 26, 2022
Outstanding (in shares)	69,380
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 3
Weighted Average [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.05
SWK Warrants – Debt – Tranche #1 [Member]
Outstanding (in shares)	51,239
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 5.86
SWK Warrants – Debt – Tranche #2 [Member]
Outstanding (in shares)	18,141
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 6.62

Note 7 - Common Stock Warrant_4

Note 7 - Common Stock Warrants - Summary of Rollforward of The Warrants Outstanding (Details)	12 Months Ended
	Dec. 31, 2023 shares
Balance (in shares)	69,380
Placement Agent Warrants, 2017 Preferred Stock Offering [Member]
Balance (in shares)	483,380
Class of Warrant or Right, Exercised During Period (in shares)	(414,000)
Balance (in shares)	69,380

Note 8 - Share-based Payment _3

Note 8 - Share-based Payment Awards (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended		12 Months Ended
	Dec. 31, 2018	Apr. 30, 2021	Jul. 31, 2017	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Jan. 01, 2023	Jan. 01, 2022	Jan. 01, 2021	Dec. 31, 2020	May 30, 2017
Common Stock, Capital Shares Reserved for Future Issuance, Increase (in shares)							1,014,124	985,040	972,512
Common Stock, Shares, Outstanding (in shares)				25,688,062	25,353,119	24,626,004	25,353,119			24,312,808
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				1,108,291
Share-Based Payment Arrangement, Expense				$ 3,137	$ 4,218	$ 3,381
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 612
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				407,808
Proceeds from Stock Options Exercised				$ 149	$ 35
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount				$ 3,601
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 2
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)		25,000		86,782	69,884
General and Administrative Expense [Member]
Class of Warrant or Right, Modification Expense					$ 244
Share-Based Payment Arrangement, Expense				$ 2,864	3,954	2,838
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense				$ 273	264	543
Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				5 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			50,000
Executive Officer [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit (in dollars per share)				$ 1.37
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit (in dollars per share)				$ 8.61
Executive Officer [Member] | General and Administrative Expense [Member]
Class of Warrant or Right, Modification Expense				$ 104
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)				10 years
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Expense				$ 239	$ 114
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 608
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 6 months
The 2017 Plan [Member] | Common Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)											5,000,000
The 2018 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				663,598
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Share Reserve as a Percent of Outstanding Common Stock				4%
The Two Thousand Eighteen Equity Incentive Plan Member
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				207,626	25,000
The 2018 Employee Stock Purchase Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				623,514
Common Stock, Capital Shares Reserved for Future Issuance, Increase (in shares)	150,000
Share-Based Payment Arrangement, Expense				$ 135	$ 128	$ 73
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 1.27	$ 1.17	$ 2.5
Common Stock, Capital Shares Reserved for Future Issuance (in shares)	150,000
Common Stock, Capital Shares Reserved for Future Issuance, Percentage Increase	1%
Employee Stock Purchase Plans, Fair Value of Common Stock Price Per Share on Offering Date, Percentage	85%
Employee Stock Purchase Plans, Fair Value of Common Stock Price Per Share on Purchase Date, Percentage	85%
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in shares)				86,782	69,884
Employee Stock Purchase Plan (ESPP), Cash Contributions to ESPP				$ 230	$ 174
The 2018 Employee Stock Purchase Plan [Member] | Accrued Liabilities [Member]
Employee-related Liabilities, Current				$ 24	$ 23

Note 8 - Share-based Payment _4

Note 8 - Share-based Payment Awards - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($) $ / shares shares
Balance, Options (in shares) | shares	4,402,292
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 4.71
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | shares	1,108,291
Issued, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 3.51
Exercised, Options (in shares) | shares	(407,808)
Exercised, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 2.23
Forfeited/Cancelled, Options (in shares) | shares	(263,549)
Forfeited/Cancelled, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 5.94
Balance, Options (in shares) | shares	4,839,226
Outstanding, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 4.57
Outstanding, Weighted Average Remaining Contractual Term (Year)	7 years 3 months 18 days
Outstanding, Aggregate Intrinsic Value | $	$ 3,467
Exercisable, Options (in shares) | shares	3,399,896
Exercisable, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 4.78
Exercisable, Weighted Average Remaining Contractual Term (Year)	6 years 8 months 12 days
Options exercisable at December 31, 2023 | $	$ 2,432
Vested and expected to vest, Options (in shares) | shares	4,839,226
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share) | $ / shares	$ 4.57
Vested and expected to vest, Weighted Average Remaining Contractual Term (Year)	7 years 3 months 18 days
Vested and expected to vest, Aggregate Intrinsic Value | $	$ 3,467

Note 8 - Share-Based Payment _5

Note 8 - Share-Based Payment Awards - Schedule of Assumptions Used to Calculate Fair Value of Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Expected volatility	70%	70%
Expected volatility			70%
Expected volatility			80%
Risk-free interest rate	3.50%	1.50%	0.90%
Risk-free interest rate	4.70%	3.90%	1.40%
Expected term (in years) (Year)	6 years 3 months 18 days	5 years 10 months 24 days	6 years
Weighted average fair value (in dollars per share)	$ 2.32	$ 2.32	$ 5.64

Note 8 - Share-based Payment _6

Note 8 - Share-based Payment Awards -Schedule of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2023 $ / shares shares
Outstanding and unvested, balance (in shares) | shares	369,606
Outstanding and unvested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares	$ 2.63
Granted (in shares) | shares	0
Granted, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares	$ 0
Vested (in shares) | shares	(91,402)
Vested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares	$ 2.63
Forfeited (in shares) | shares	(4,000)
Forfeited, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares	$ 2.63
Outstanding and unvested, balance (in shares) | shares	274,204
Outstanding and unvested, Weighted Average Grant-Date Fair Value Per Unit (in dollars per share) | $ / shares	$ 2.63

Note 9 - Basic and Diluted Ne_3

Note 9 - Basic and Diluted Net Loss per Common Share (Details Textual) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	5,418,251	5,494,153	4,286,687

Note 9 - Basic and Diluted Ne_4

Note 9 - Basic and Diluted Net Loss per Common Share - Schedule of Earnings (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net income (loss)	$ (936)	$ (9,021)	$ (1,955)
Weighted average number of common shares outstanding, basic and diluted (in shares)	25,645,366	25,145,657	25,207,299
Net loss per share, basic and diluted (in dollars per share)	$ (0.04)	$ (0.36)	$ (0.08)

Note 10 - Related-party Trans_2

Note 10 - Related-party Transactions (Details Textual) - USD ($) $ in Thousands			1 Months Ended		9 Months Ended	12 Months Ended
	Feb. 18, 2019	Aug. 11, 2017	May 31, 2021	Apr. 30, 2021	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Proceeds from Sale of Machinery and Equipment			$ 700			$ 0	$ 0	$ 700
Gain (Loss) on Disposition of Property Plant Equipment			$ 181			$ 0	0	$ 181
Related Party, Bausch Health [Member] | Royalty [Member]
Related Party Transaction, Rate	12%
Harrow Health Inc [Member]
Common Stock, Shares Owned (in shares)						1,982,000
Harrow Health Inc [Member] | Eton Pharmaceuticals [Member]
Equity Method Investment, Ownership Percentage						7.70%
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member]
Related Party Transaction, Terms (Year)		10 years
Related Party Transaction, Terms, Renewal (Year)		2 years
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member] | Royalty [Member]
Related Party Transaction, Rate		10%
The Eyemax Agreement [Member] | Related Party, Eyemax LLC [Member] | Research and Development Expense [Member]
Related Party Transaction, Amounts of Transaction		$ 250
Covenant Based on Sale of First Commercial Product [Member] | Related Party, Eyemax LLC [Member]
Related Party Transaction, Amounts of Transaction		$ 500
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member]
Related Party Transaction, Amounts of Transaction						$ 0	$ 0
Revenues					$ 1,840
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member] | Covenant Based on Approval by The FDA [Member]
Related Party Transaction, Amounts of Transaction	$ 250
The Amended Agreement [Member] | Related Party, Eyemax LLC [Member] | Covenant Based on Sale of First Commercial Product [Member]
Related Party Transaction, Amounts of Transaction	$ 500
Chief Executive Officer [Member] | Harrow Health Inc [Member] | Restricted Stock Units (RSUs) [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)				25,000

Note 11 - Leases (Details Textu

Note 11 - Leases (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Nov. 30, 2022	Oct. 31, 2020
Operating Lease, Right-of-Use Asset	$ 92	$ 188		$ 188	$ 195
Operating Lease, Liability	$ 75			$ 188	$ 195
Lessee, Operating Lease, Discount Rate	7.80%			8.60%	5.40%
Operating Lease, Expense	$ 77	86	$ 113
Operating Lease, Payments	88	88	83
Operating Lease, Right-of-Use Asset, Periodic Reduction	$ 67	62	88
Operating Lease, Weighted Average Remaining Lease Term (Year)	1 year 3 months
Operating Lease, Weighted Average Discount Rate, Percent	8.60%
Research and Development Expense [Member]
Operating Lease, Cost	$ 0	0	9
General and Administrative Expense [Member]
Operating Lease, Cost	$ 67	$ 82	$ 86

Note 11 - Leases - Schedule of

Note 11 - Leases - Schedule of Lease-related Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022	Nov. 30, 2022	Oct. 31, 2020
Operating Lease, Right-of-Use Asset	$ 92	$ 188	$ 188	$ 195
Liabilities
Operating lease liabilities, net of current portion	22	$ 107
Total operating lease liabilities	75		$ 188	$ 195
Noncurrent Assets [Member]
Operating Lease, Right-of-Use Asset	92
Accrued Liabilities [Member]
Liabilities
Operating lease liabilities, current	$ 53

Note 11 - Leases - Schedule o_2

Note 11 - Leases - Schedule of Future Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Nov. 30, 2022	Oct. 31, 2020
Total	$ 81
2023	58
2024	23
2025	0
Less: Imputed interest	(6)
Total lease liabilities	$ 75	$ 188	$ 195

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Percentage for Valuation Reserve Against Deferred Tax Assets	100%	100%
Deferred Tax Assets, Gross	$ 21,516	$ 21,632
Operating Loss Carryforwards	54,190
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration	$ 54,190

Note 12 - Income Taxes - Schedu

Note 12 - Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Federal	$ 61	$ 0	$ 0
State	186	0	0
Total current expense	247	0	0
Federal	(85)	2,272	460
State	(31)	812	185
Change in valuation allowance	116	(3,084)	(645)
Total deferred expense	0	0	0
Income tax expense	$ 247	$ 0	$ 0

Note 12 - Income Taxes - Compon

Note 12 - Income Taxes - Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Net operating losses	$ 15,447	$ 17,183
Stock-based expenses	3,372	3,090
Accruals and other	2,697	1,359
Total deferred tax assets	21,516	21,632
Valuation allowance	(21,516)	(21,632)
Net deferred tax assets	$ 0	$ 0

Note 12 - Income Taxes - Sche_2

Note 12 - Income Taxes - Schedule of Reconciliation of Statutory Federal Tax Rate (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Provision (benefit) at statutory rate	21%	21%	21%
Provision (benefit) at statutory rate	(21.00%)	(21.00%)	(21.00%)
Permanent items (primarily warrants and stock compensation)	39.10%	(3.30%)	(2.50%)
State tax benefit	6.50%	(8.70%)	(9.50%)
Federal rate change	0%	0%	0%
Other items	0%	0%	0%
Increase (decrease) in valuation allowance	(30.70%)	(33.00%)	(33.00%)
Increase (decrease) in valuation allowance	30.70%	33%	33%
Income tax expense	35.90%	0%	0%

Note 13 - Employee Savings Pl_2

Note 13 - Employee Savings Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	100%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 242	$ 172	$ 154

Note 14 - Commitments and Con_2

Note 14 - Commitments and Contingencies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands

1 Months Ended

12 Months Ended

Sep. 13, 2022

Oct. 28, 2021

Jun. 15, 2021

Mar. 26, 2020

Nov. 30, 2023

Oct. 31, 2023

Jul. 31, 2023

Jun. 30, 2022

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Mar. 14, 2023

Mar. 27, 2020

Jan. 23, 2019

Share Price (in dollars per share)

$ 2.32

$ 2.32

$ 5.64

Research and Development Expense, Total

$ 3,322

$ 3,996

$ 6,235

Cost of Goods and Services Sold

10,581

6,933

2,827

Common Stock [Member]

Share Price (in dollars per share)

$ 3.33

Indemnification Rights and Agreements [Member]

Other Commitment, Total

0

0

License [Member]

Cost of Goods and Services Sold

1,000

1,640

1,500

Carglumic Acid Tablets [Member]

Payments to Acquire Marketing Rights

$ 3,250

Commitment, Allocation of Profits, Percentage

50%

Betaine Anhydrous [Member]

Payments to Acquire Marketing Rights

$ 2,000

$ 125

Commitment, Allocation of Profits, Percentage

65%

Betaine Anhydrous [Member] | Obligation Based on Commercial Success [Member]

Other Commitment, Total

$ 1,000

FDA-Approved ANDA For Nitisinone [Member]

Payments to Acquire Marketing Rights

$ 150

Commitment, Allocation of Profits, Percentage

80%

FDA-Approved ANDA For Nitisinone [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]

Payments to Acquire Marketing Rights

$ 500

Azurity Pharmaceuticals, Inc. (“Azurity”) [Member]

Revenue, Additional Based on Event and Sales-based Milestones Achievements

$ 5,500

Azurity Pharmaceuticals, Inc. (“Azurity”) [Member] | Milestone Method [Member]

Revenues

27,500

Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Successful Manufacturing of Registration Batches [Member]

Other Commitment, Total

$ 450

Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on Acceptance of FDA of NDA for product [Member]

Other Commitment, Total

$ 200

Royalties, Percentage of Net Sales,

12.50%

Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Obligation Based on First Commercial Sale of Product [Member]

Other Commitment, Total

$ 250

Royalties, Percentage of Net Sales,

17%

Tulex Pharmaceuticals, Inc. (“Tulex”) [Member] | Topiramate (fka ET-101) [Member]

Accounts Receivable, after Allowance for Credit Loss, Total

$ 5,000

Liqmeds Worldwide Limited (“LMW”) [Member] | Licensing and Supply Agreement (the “Agreement”) [Member] | Obligation Based on Issuance of Orange-book Listed Patent [Member]

Other Commitment, Total

$ 650

Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]

Aggregate Value of Licensing Milestone Included in Research and Development Expense

$ 1,000

Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Common Stock [Member]

Stock Issued During Period, Shares, New Issues (in shares)

379,474

Stock Issued During Period, Value, New Issues

$ 1,264

Diurnal Limited [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member] | Obligation Based on Exclusivity Status from FDA [Member]

Other Commitment, Total

$ 2,500

Diurnal Limited [Member] | License [Member] | Exclusive Licensing and Supply Agreement (the “Alkindi License Agreement”) [Member]

Commitment, Milestone Fee

$ 3,500

Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member]

Research and Development Expense, Total

$ 500

Royalty on Net Sales of Products, Percent

10%

Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Development Milestones [Member]

Other Commitment, Total

$ 3,500

Crossject [Member] | U.S. and Canadian rights to Crossject S.A.’s [Member] | Obligation Based on Commercial Success [Member]

Other Commitment, Total

$ 6,000

Dr. Reddy’s [Member] | License [Member]

Revenues

$ 5,000

Sintetica [Member]

Cost of Goods and Services Sold

$ 812